Fundraising Fox
Gatehouse Bio
Waltham, US · Founded 2017 · Delaware corporation · 3 known investors
Find your way into Gatehouse Bio
Sign up to see every warm intro you have to Gatehouse Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gatehouse Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Gatehouse Bio develops AI-powered therapeutics for pulmonary, cardiac, neurological, and autoimmune diseases by decoding small RNAs using their Code-Breaker platform to design precision medicine treatments.
Founders & leadership
Gatehouse Bio was founded in 2017 by David W. Salzman.
DW
David W. SalzmanFounder & CEODavid W. Salzman is an ASCP-certified molecular biologist with experience developing biomarker assays for clinical and preclinical applications, including work on NGS-based diagnostics and commercial diagnostic kits. He founded Gatehouse Bio, which develops AI-powered therapeutics targeting pulmonary, cardiac, neurological, and autoimmune diseases.
NF
Neal FosterNamed on SEC filing
DW
David W. Salzman, Ph.D.Named on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$5.4M disclosed across 1 round · 2020
▶$5.4MraisedJan 2021 · 28 investors · BiotechnologyRule 506(b)
▶$5.4MraisedJan 2021 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neal FosterExecutive Officer, Director
- David W. Salzman, Ph.D.Executive Officer, Director
- Offering amount
- $5.4M
- Amount sold
- $5.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Gate BioGate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment. The company operates in the drug discovery and development space.
Syndeio BiosciencesSyndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's. Its proprietary Boost Platform models synapse pharmacology, and its pipeline includes NMDA receptor positive allosteric modulators (zelquistinel and apimostinel) in Phase 2 clinical trials.
Precision BioSciencesPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
a16z Speedruna16z is a venture capital firm that invests in seed to growth-stage technology companies across artificial intelligence, healthcare, consumer, crypto, enterprise, fintech, gaming, and infrastructure sectors. The firm leverages a large team of operators and ex-founders to support portfolio companies across multiple stages of development.
Gate2BrainGate2Brain develops therapeutics designed to cross biological barriers, particularly the blood-brain barrier, using a proprietary peptide-based technology platform. The company focuses on biotech drug development for conditions requiring brain delivery.
AlumniAstraZeneca develops and markets pharmaceutical products, vaccines, and biologics across oncology, cardiovascular disease, respiratory and immunology, and rare disease areas, serving patients and healthcare providers globally.
Companies working in the same space as Gatehouse Bio.
Frequently asked questions
- What does Gatehouse Bio do?
- Gatehouse Bio develops AI-powered therapeutics for pulmonary, cardiac, neurological, and autoimmune diseases by decoding small RNAs using their Code-Breaker platform to design precision medicine treatments.
- Who founded Gatehouse Bio?
- Gatehouse Bio was founded by David W. Salzman in 2017.
- Who are Gatehouse Bio's investors?
- Gatehouse Bio's investors include Claritas Capital, Front Row Fund, SOSV.
- How much funding has Gatehouse Bio raised?
- Gatehouse Bio has disclosed $5.4M raised across 1 round.
- Where is Gatehouse Bio headquartered?
- Gatehouse Bio is headquartered in Waltham, US.